文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

地塞米松用于全国队列中COVID-19住院患者

Dexamethasone for Inpatients With COVID-19 in a National Cohort.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论全国多中心回顾性队列显示,因COVID-19呼吸道疾病住院患者早期使用地塞米松与需吸氧或MV/ECMO者死亡率或转临终关怀出院 odds 降低相关,无需吸氧或仅NIPPV者未见降低。

该回顾性、倾向评分加权队列研究纳入2020年7月1日至2021年10月31日美国156家医院网络内因COVID-19呼吸道疾病住院至少48小时的成人患者80699例。暴露为入院或氧支持升级后48小时内使用全身地塞米松,主要终点为全因住院死亡或转临终关怀出院。经倾向评分重叠加权后,地塞米松与需吸氧患者(aOR 0.92;95% CI 0.86-0.98)及需MV和/或ECMO患者(aOR 0.82;95% CI 0.68-0.99)复合终点降低相关;无需吸氧组(aOR 0.90;95% CI 0.78-1.03)和NIPPV组(aOR 0.87;95% CI 0.73-1.04)未见降低。合并症更多者获益更大。

要点

  • 需吸氧的COVID-19住院患者早期使用地塞米松与住院死亡或转临终关怀出院 odds 降低相关(aOR 0.92;95% CI 0.86-0.98)。
  • 需机械通气和/或ECMO的患者早期使用地塞米松与复合终点降低相关(aOR 0.82;95% CI 0.68-0.99)。
  • 无需吸氧患者使用地塞米松未见复合终点降低(aOR 0.90;95% CI 0.78-1.03)。
  • 需NIPPV患者使用地塞米松未见复合终点降低(aOR 0.87;95% CI 0.73-1.04)。
  • 合并症更多的患者从地塞米松使用中获益更大。

适用人群与场景

  • 2020年7月1日至2021年10月31日在美国156家医院网络内因COVID-19呼吸道疾病住院至少48小时的成人患者。
  • 按入院后48小时内氧支持需求分层:无需补充氧13040例(16.2%)、需补充氧56368例(69.8%)、需NIPPV 7618例(9.4%)、需MV和/或ECMO 3673例(4.6%)。

处置流程与药物剂量

  • 全身地塞米松在入院或氧支持升级后48小时内给药(原文未写明具体剂量、途径和疗程)。

研究设计与关键结果

  • 回顾性、倾向评分加权队列研究,纳入80699例成人COVID-19住院患者(中位[IQR]年龄64[52-76]岁;女性37606例[46.6%];黑人13230例[16.4%]、白人49222例[60.9%]、其他种族18247例[22.6%]、西班牙裔20340例[25.2%])。
  • 经倾向评分重叠加权后,需补充氧组早期使用地塞米松与住院死亡或转临终关怀出院复合终点降低相关(aOR 0.92;95% CI 0.86-0.98)。
  • 需MV和/或ECMO组早期使用地塞米松与复合终点降低相关(aOR 0.82;95% CI 0.68-0.99)。
  • 无需补充氧组使用地塞米松未见复合终点降低(aOR 0.90;95% CI 0.78-1.03)。
  • 需NIPPV组使用地塞米松未见复合终点降低(aOR 0.87;95% CI 0.73-1.04)。
  • 合并症更多的患者从地塞米松使用中获益更大。

证据类型、等级与局限

  • 证据类型:回顾性、倾向评分加权队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些结果支持继续对COVID-19住院患者使用全身地塞米松。
  • 原文结果提示,地塞米松的获益主要体现在需要补充氧或MV和/或ECMO的患者,无需补充氧或仅需NIPPV的患者未见获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Limited effective therapeutics are available to hospitalized patients with COVID-19. Clinical trials and observational studies have shown varying effects of systemic corticosteroids, including dexamethasone, in hospitalized patients with COVID-19, with limited descriptions of important patient subgroups.

OBJECTIVE: To examine the clinical use of dexamethasone for hospitalized patients with COVID-19 respiratory illness and to explore the heterogeneity of treatment outcomes across different subgroups.

DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, propensity score-weighted cohort study of adult patients hospitalized for at least 48 hours for COVID-19 respiratory illness between July 1, 2020, and October 31, 2021, at a large health care network of 156 hospitals across the US. Data analysis was performed from March 2022 to February 2023.

EXPOSURES: Systemic dexamethasone administered within 48 hours of either admission or escalation in oxygen support.

MAIN OUTCOMES AND MEASURES: All-cause in-hospital mortality or discharge to hospice.

RESULTS: A total of 80 699 patients who met the eligibility criteria were identified (median [IQR] age, 64 [52-76] years; 37 606 women [46.6%]); 13 230 patients (16.4%) identified as Black, 49 222 (60.9%) as White, 18 247 (22.6%) as other race, and 20 340 (25.2%) as Hispanic ethnicity. Of these patients, 13 040 (16.2%) did not require supplemental oxygen within 48 hours of admission, 56 368 (69.8%) required supplemental oxygen, 7618 (9.4%) required noninvasive positive pressure ventilation (NIPPV), and 3673 (4.6%) required mechanical ventilation (MV) and/or extracorporeal membrane oxygenation (ECMO). After adjustment by propensity score overlap weighting, early use of dexamethasone was associated with reduction in a composite outcome of in-hospital mortality or discharge to hospice for patients receiving supplemental oxygen (aOR, 0.92; 95% CI, 0.86-0.98) and MV and/or ECMO (aOR, 0.82; 95% CI, 0.68-0.99). In contrast, all-cause inpatient mortality or discharge to hospice was not lower for patients who received dexamethasone in the no supplemental oxygen group (aOR, 0.90; 95% CI, 0.78-1.03) and in the NIPPV group (aOR, 0.87; 95% CI, 0.73-1.04). Importantly, patients with more comorbidities had greater benefit from dexamethasone use.

CONCLUSIONS AND RELEVANCE: In this national multicenter cohort study of inpatients with COVID-19, early administration of dexamethasone was associated with significantly reduced odds of mortality or discharge to hospice in those requiring supplemental oxygen or MV and/or ECMO but not in those requiring no supplemental oxygen or NIPPV. These results support the continued use of systemic dexamethasone in patients hospitalized with COVID-19.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Mourad A, Thibault D, Holland TL, et al. Dexamethasone for Inpatients With COVID-19 in a National Cohort. JAMA Netw Open. 2023. PMID: 37067800. doi:10.1001/jamanetworkopen.2023.8516

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。